Drug Trial Radar · NCT05456880
BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease
Last checked: Nov 19, 2026Latest source record: Dec 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
15
Planned (sponsor's estimate)
Start
Aug 30, 2022
Primary completion
Feb 2028
Study completion Feb 2028
Sponsor
- Lead sponsor
- Beam Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 13, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 35 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, single-arm, multicenter, Phase 1/2 study evaluating the safety and efficacy of the administration of autologous base edited CD34+ HSPCs (BEAM-101) in patients with severe SCD
Conditions
- Sickle Cell Disease
Interventions
BEAM-101Biological
Single dose of BEAM-101 administered by IV following myeloablative conditioning with busulfan
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in annualized number of severe VOCs (Vascular-occlusive Crisis) relative to baselineTime frame: 6 months to time of analysis as compared to baseline
- Proportion of patients with successful neutrophil engraftmentTime frame: BEAM-101 administration to month 24
- Time to neutrophil engraftmentTime frame: BEAM-101 administration to month 24
- Time to platelet engraftmentTime frame: BEAM-101 administration to month 24
- Transplant-related mortality within 100 days after beam-101 treatmentTime frame: BEAM-101 administration to day 100
- Safety and tolerability assessments based on frequency, severity and seriousness of adverse events (AE's)Time frame: BEAM-101 administration through month 24
Locations
19 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Phoenix Children's Hospital
Phoenix, Arizona
Mayo Clinic Florida
Jacksonville, Florida
University of Miami
Miami, Florida
Children's Healthcare of Atlanta - Aflac Cancer and Blood Disorders Center - Egleston Hospital
Atlanta, Georgia
Boston Children's Hospital
Boston, Massachusetts
Henry Ford Cancer Center
Detroit, Michigan
University of Minnesota
Minneapolis, Minnesota
Washington University School of Medicine in St. Louis
St Louis, Missouri
Hackensack University Medical Center
Hackensack, New Jersey
Columbia University Irving Medical Center
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
University Hospitals Cleveland Medical Center
Cleveland, Ohio
The Cleveland Clinic Foundation
Cleveland, Ohio
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
Medical University of South Carolina
Charleston, South Carolina
St Jude Children's Research Hospital
Memphis, Tennessee
The Children's Hospital at TriStar Centennial
Nashville, Tennessee
Medical College of Wisconsin
Milwaukee, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.